Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06406348 | A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants | PHASE1 | COMPLETED | 53 | — | — | May 9, 2024 | Apr 22, 2025 | Jul 17, 2025 | 1 | United States |
Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Single Ascending Dose (SAD) cohorts |
| Placebo | PLACEBO_COMPARATOR | Single Ascending Dose (SAD) cohorts |
| Name | Type | Description |
|---|---|---|
| ALIA-1758 | DRUG | Intravenous or subcutaneous doses |
| Placebo | OTHER | Intravenous or subcutaneous doses |
Key Inclusion Criteria: * Participants must understand the nature of the trial and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any trial-related procedures. * Healthy as determined by the Investigator, based on a medical evaluati...